What is the target total testosterone level and recommended dosing regimen for testosterone supplementation in an adult male?

Target Testosterone Levels and Dosing for Testosterone Supplementation in Adult Males

Goal Testosterone Level

The target testosterone level during treatment should be in the mid-normal range, typically between 400-700 ng/dL (approximately 14-24 nmol/L). 1, 2

The Endocrine Society guidelines specifically recommend aiming for testosterone levels in the mid-normal range during treatment, rather than targeting the upper or lower limits of normal. 1, 2 This approach balances efficacy with safety considerations, particularly regarding cardiovascular and hematologic effects.

Diagnostic Threshold Before Initiating Therapy

• Testosterone deficiency is defined as total testosterone < 300 ng/dL (10.41 nmol/L) measured on two separate early-morning samples, accompanied by relevant clinical symptoms. 3
• Morning measurements are essential because testosterone levels fluctuate throughout the day, with peak levels occurring in early morning. 1, 2
• Confirmation with a second measurement prevents misdiagnosis from transient low values. 1, 2

Recommended Dosing Regimens

Intramuscular Testosterone Enanthate (Preferred)

Intramuscular formulations are recommended over transdermal preparations due to comparable efficacy at substantially lower cost. 4, 3

• 200 mg every 2 weeks is the most commonly recommended regimen, effectively suppressing elevated LH to normal levels while maintaining testosterone in the normal range. 5
• 300 mg every 3 weeks is an alternative effective regimen with less frequent administration. 5
• These doses produce testosterone concentrations that fluctuate largely within the normal range between injections. 5

Transdermal Testosterone Gel (Alternative)

• 60 mg daily (3 g of 2% gel) applied to the thighs maintains average testosterone concentrations around 6.52 μg/L (approximately 650 ng/dL) in most hypogonadal men. 6
• This dose achieved a minimum concentration (C_min) of 3.83 μg/L with 96% of men maintaining levels above 3.0 μg/L throughout the day. 6
• Dose adjustments to lower (40 mg) or higher (80 mg) doses may be needed based on follow-up levels. 6

Dose Titration Strategy

Nine of the reviewed trials adjusted dosing to achieve targeted testosterone levels rather than using fixed doses. 4 This approach is clinically superior:

• Measure testosterone levels 3-6 months after initiating therapy
• Adjust dose if levels fall outside the mid-normal range (400-700 ng/dL)
• For intramuscular injections, measure levels midway between injections to assess average exposure
• For transdermal preparations, measure morning levels before application

Clinical Indications and Monitoring

Appropriate Indications

Testosterone therapy should be prescribed only for men with age-related low testosterone who have sexual dysfunction and want to improve sexual function. 4, 3

• The American College of Physicians specifically recommends against prescribing testosterone for low energy, reduced vitality, impaired physical function, or cognitive decline. 4, 3
• Sexual function shows small but clinically meaningful improvements (effect size 0.35-0.45), while other symptoms show minimal benefit. 4

Mandatory Reassessment

Reevaluate symptoms within 12 months and discontinue testosterone if there is no improvement in sexual function. 4

This prevents indefinite continuation of therapy in non-responders and reduces unnecessary exposure to potential long-term risks.

Absolute Contraindications

Testosterone therapy must not be initiated in men with: 1, 2

• Breast or prostate cancer
• PSA > 3 ng/mL without urological evaluation (or > 4 ng/mL in lower-risk men)
• Hematocrit > 50%
• Severe lower urinary tract symptoms (IPSS > 19)
• Untreated severe obstructive sleep apnea
• Uncontrolled or poorly controlled heart failure (Class III or IV)

Monitoring During Treatment

• Hematocrit monitoring is critical as testosterone increases red blood cell production and can cause erythrocytosis. 7
• PSA levels should be monitored in men over 40 years
• Testosterone levels should be checked to ensure mid-normal range achievement
• Symptom reassessment at 12 months is mandatory 4

Important Caveats

• Up to 25% of men receiving testosterone therapy do not meet diagnostic criteria, and nearly half are not monitored appropriately. 3 This represents a significant quality gap in real-world practice.
• Long-term cardiovascular safety data remain limited, though the recent TRAVERSE trial showed no significant increase in major adverse cardiovascular events. 7
• Evidence is insufficient regarding long-term prostate cancer risk. 3
• Most efficacy data come from trials lasting less than 1 year, so long-term benefits remain uncertain. 4